Diagnostic Yield of Vitreous Biopsy in Sarcoid Uveitis
NCT00609687 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150
Last updated 2013-04-11
Summary
The usefulness of diagnostic vitrectomy in patients with suspected sarcoidosis with posterior segment involvement (in whom a diagnosis cannot be determined by conventional methods) has not been well described. We hypothesized that diagnostic vitrectomy would help establish the diagnosis in these challenging cases. Herein, we evaluated the diagnostic yield of vitreous biopsy in patients with suspected sarcoidosis-associated uveitis that affected the posterior segment.This is a retrospective interventional case series. Cases of intermediate, posterior or panuveitis that could not be characterized by clinical examination, ancillary, and laboratory tests were considered for diagnostic pars plana vitrectomy. Retrospective chart review was conducted on consecutive eyes that underwent diagnostic, or diagnostic and therapeutic vitrectomy by a single surgeon from January 1989 to June 2006.
Conditions
- Sarcoidosis-associated Ocular Inflammation
Interventions
- PROCEDURE
-
Diagnostic Vitrectomy
Three-port, 20-gauge pars plana vitrectomy instrumentation was utilized. An infusion line was inserted into one sclerotomy and secured to the globe. A second sclerotomy was made, and a fiberoptic light pipe was immediately inserted to minimize vitreous egress. A third sclerotomy was created, and the vitreous cutter was inserted. To obtain an undiluted vitreous sample, the vitreous was cut mechanically with the vitreous cutter, while the assistant surgeon simultaneously manually aspirated the vitreous. After sufficient undiluted sample was obtained, infusion fluid was allowed to enter the eye and a diluted vitreous sample was obtained in a similar manner. The samples were personally carried to the clinical laboratories by the operating surgeon. Vitreous fluid analysis was guided by clinical suspicion based on the pre-operative differential diagnosis and the intraoperative posterior segment appearance.
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Glenn J Jaffe, MD · Duke University Eye Center
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-01-31
- Primary Completion
- 2007-10-31
- Completion
- 2008-01-31
Countries
- United States
Study Locations
More Related Trials
-
Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study
NCT06085079 ·Status: RECRUITING ·Phase: PHASE4
-
Evaluation of Birdshot Retine Choroidopathy Treatment by Either Steroid or Interferon alpha2a
NCT00508040 ·Status: COMPLETED ·Phase: PHASE2
-
Analysis of Eye Tissue
NCT00001224 ·Status: COMPLETED
-
Study of Risk Factors for Therapeutic Failure in Chronic Non-Infectious Uveitis After First-Line Immunosuppressive Therapy
NCT06821971 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluation and Treatment of Patients With Inflammatory Eye Diseases
NCT00006188 ·Status: COMPLETED
-
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
NCT02258867 ·Status: TERMINATED ·Phase: PHASE3
-
Conbercept in Choroidal Neovascularization Secondary to Uveitis
NCT02934841 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
NCT01526889 ·Status: COMPLETED ·Phase: PHASE2
-
Uveitis Gene-Expression Profiling
NCT00874471 ·Status: COMPLETED
-
Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome
NCT00955630 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
NCT00996437 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy
NCT01746563 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Screening for NEI Clinical Studies
NCT00001734 ·Status: COMPLETED
-
Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles
NCT07262437 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Screening for Research Subjects With Anterior Segment Diseases
NCT00088348 ·Status: COMPLETED
-
The Cohort Study of Uveitis Patients
NCT05727540 ·Status: RECRUITING
-
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
NCT00070759 ·Status: COMPLETED ·Phase: PHASE2
-
Can COVID-19 Persist in Intraocular Fluid?
NCT04945850 ·Status: COMPLETED
-
A Pilot Study for the Treatment of Iris Neovascularization With Macugen
NCT00295828 ·Status: COMPLETED ·Phase: PHASE1
-
Intravitreal Sirolimus as Therapeutic Approach to Uveitis
NCT01280669 ·Status: WITHDRAWN ·Phase: PHASE2
-
Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV
NCT05662943 ·Status: COMPLETED
-
Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration
NCT01628354 ·Status: COMPLETED ·Phase: PHASE4
-
Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis
NCT00043667 ·Status: COMPLETED ·Phase: PHASE2
-
Intravitreal Celecoxib for Chronic Uveitis
NCT02131012 ·Status: TERMINATED ·Phase: PHASE1
-
Daclizumab and Sirolimus to Treat Uveitis
NCT00078689 ·Status: COMPLETED ·Phase: PHASE1